Epigenetics in cancer S Sharma, TK Kelly, PA Jones Carcinogenesis 31 (1), 27-36, 2010 | 3342 | 2010 |
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer EM Wolff, HM Byun, HF Han, S Sharma, PW Nichols, KD Siegmund, ... PLoS genetics 6 (4), e1000917, 2010 | 355 | 2010 |
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival DD De Carvalho, S Sharma, JS You, SF Su, PC Taberlay, TK Kelly, ... Cancer Cell 21 (5), 655-667, 2012 | 327 | 2012 |
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA S Jeong, G Liang, S Sharma, JC Lin, SH Choi, H Han, CB Yoo, G Egger, ... Molecular and cellular biology 29 (19), 5366-5376, 2009 | 243 | 2009 |
The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies B Vangamudi, TA Paul, PK Shah, M Kost-Alimova, L Nottebaum, X Shi, ... Cancer research 75 (18), 3865-3878, 2015 | 240 | 2015 |
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight DJ Weisenberger, BN Trinh, M Campan, S Sharma, TI Long, ... Nucleic acids research 36 (14), 4689-4698, 2008 | 165 | 2008 |
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance S Sharma, DD De Carvalho, S Jeong, PA Jones, G Liang PLoS genetics 7 (2), e1001286, 2011 | 142 | 2011 |
Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R … PP Kung, P Bingham, A Brooun, M Collins, YL Deng, D Dinh, C Fan, ... Journal of medicinal chemistry 61 (3), 650-665, 2018 | 105 | 2018 |
The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review HS Rugo, I Jacobs, S Sharma, F Scappaticci, TA Paul, ... Advances in therapy 37, 3059-3082, 2020 | 78 | 2020 |
Emerging therapeutic targets for patients with advanced prostate cancer F Saad, N Shore, T Zhang, S Sharma, HK Cho, IA Jacobs Cancer treatment reviews 76, 1-9, 2019 | 42 | 2019 |
Lysine methyltransferase G9a is not required for DNMT3A/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells S Sharma, DS Gerke, HF Han, S Jeong, MR Stallcup, PA Jones, G Liang Epigenetics & chromatin 5, 1-12, 2012 | 28 | 2012 |
Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state W Yan, CY Chung, T Xie, M Ozeck, TC Nichols, J Frey, AR Udyavar, ... Molecular Oncology 16 (6), 1309-1328, 2022 | 17 | 2022 |
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations J Qiu, S Sharma, RA Rollins, TA Paul Future Medicinal Chemistry 12 (15), 1415-1430, 2020 | 17 | 2020 |
Iodine-mediated oxidative cyclization of 2-(Pyridin-2-yl) acetate derivatives with alkynes: condition-controlled selective synthesis of multisubstituted indolizines L He, Y Yang, X Liu, G Liang, C Li, D Wang, W Pan Synthesis 52 (03), 459-470, 2020 | 16 | 2020 |
Corona effects on eHv AC transmission lines S Sharma, K Goel, A Gupta, H Kumar International Journal of Scientific Research Engineering & Technology 1 (5 …, 2012 | 13 | 2012 |
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation S Sharma, J Chung, S Uryu, A Rickard, N Nady, S Khan Cancer Res. 81 (Suppl. 13), 1130-1130, 2021 | 11 | 2021 |
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer S Sharma, CY Chung, S Uryu, J Petrovic, J Cao, A Rickard, N Nady, ... Cell Chemical Biology 30 (10), 1191-1210. e20, 2023 | 6 | 2023 |
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of epigenetic regulator enhancer of zeste homolog 2 S Yamazaki, HJ Gukasyan, H Wang, S Uryu, S Sharma Journal of Pharmacology and Experimental Therapeutics 373 (2), 220-229, 2020 | 5 | 2020 |
488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and … M Schweizer, KD Penkov, AW Tolcher, AD Choudhury, V Doronin, ... Annals of Oncology 33, S763-S764, 2022 | 4 | 2022 |
Influence of previously ingested wheat on fasting breath hydrogen in celiac patients SV Rana, S Sharma, SK Sinha, J Kaur, KK Prasad, K Singh Digestive diseases and sciences 54, 1276-1279, 2009 | 3 | 2009 |